Abstract: A medical device, a stapler, and a rotation locking mechanism, the medical device including a handheld mechanism, a connecting mechanism, and an actuator. The connecting mechanism is connected to the handheld mechanism and the actuator. The handheld mechanism is internally provided with a first rotation locking mechanism and a first transmission mechanism connected to the first rotation locking mechanism. A second rotation locking mechanism matching the first rotation locking mechanism is disposed on the connecting mechanism. When the first transmission mechanism is in a first state, the first rotation locking mechanism and the second rotation locking mechanism are in an unlocked state, such that the connecting mechanism is rotatable. When the first transmission mechanism is in a second state, the first rotation locking mechanism and the second rotation locking mechanism are in a locked state, such that the connecting mechanism is locked, thereby improving surgery safety and surgery efficiency.

Abstract: A squeeze-type electrode connector, relating to a technical field of electrodes, includes a shell and a clamping portion. The shell includes a connecting portion with a cavity defined therein. The connecting portion is made of an elastic material. The clamping portion includes a first metal sheet and a second metal sheet disposed on two sides of an interior of the cavity. A through-hole is defined through the first metal sheet. The first metal sheet is in staggered contact with the second metal sheet. The second metal sheet overlaps a part of the through-hole, so as to allow the through-hole to clamp an electrode sheet.

Abstract: A medical device, a stapler, and a rotation locking mechanism, the medical device including a handheld mechanism, a connecting mechanism, and an actuator. The connecting mechanism is connected to the handheld mechanism and the actuator. The handheld mechanism is internally provided with a first rotation locking mechanism and a first transmission mechanism connected to the first rotation locking mechanism. A second rotation locking mechanism matching the first rotation locking mechanism is disposed on the connecting mechanism. When the first transmission mechanism is in a first state, the first rotation locking mechanism and the second rotation locking mechanism are in an unlocked state, such that the connecting mechanism is rotatable. When the first transmission mechanism is in a second state, the first rotation locking mechanism and the second rotation locking mechanism are in a locked state, such that the connecting mechanism is locked, thereby improving surgery safety and surgery efficiency.

Abstract: The invention provides a double-power-supply switching control system for a welding machine and method. The welding machine double-power-supply switching control method comprises the steps of: continuously detecting and modifying an input voltage signal by a signal modification unit; under the control of a control unit, judging, by a judgment unit, whether to perform voltage doubling, controlling to execute voltage doubling switching action, and locking an actual input voltage mode of a welding machine by a locking unit; and finally outputting matched output current by a power supply output unit.

Abstract: The invention provides a double-power-supply switching control system for a welding machine and method. The welding machine double-power-supply switching control method comprises the steps of: continuously detecting and modifying an input voltage signal by a signal modification unit; under the control of a control unit, judging, by a judgment unit, whether to perform voltage doubling, controlling to execute voltage doubling switching action, and locking an actual input voltage mode of a welding machine by a locking unit; and finally outputting matched output current by a power supply output unit.

Abstract: Provided are methods for optimizing therapy of, treating a patient having, or selecting (identifying) patients who will benefit from treatment for, a cancer (e.g., a non-hematological cancer; e.g., a gynecological cancer). The methods comprise determining whether the patient will benefit from treatment with an ErbB3 inhibitor (e.g., an anti-ErbB3 antibody), with or without either a taxane or an aromatase inhibitor, or with a taxane or an aromatase inhibitor in the absence of an ErbB3 inhibitor, based on levels of particular biomarkers and combinations of biomarkers measured in a biological sample obtained from the patient. The methods further comprise optimizing the patient's therapy, selecting the patient for treatment, or treating the patient accordingly. In various aspects the biological samples are sections of a biopsy (e.g., a formalin fixed paraffin embedded biopsy). In oth6er aspects the biomarkers are proteins and/or nucleic acids.

Abstract: Methods for predicting a therapeutic response in a patient (e.g., a cancer patient) to ErbB3 inhibitors, and methods of treating a cancer patient with targeted therapies.

Abstract: Provided are methods for optimizing therapy of, treating a patient having, or selecting (identifying) patients who will benefit from treatment for, a cancer (e.g., a non-hematological cancer; e.g., a gynecological cancer). The methods comprise determining whether the patient will benefit from treatment with an ErbB3 inhibitor (e.g., an anti-ErbB3 antibody), with or without either a taxane or an aromatase inhibitor, or with a taxane or an aromatase inhibitor in the absence of an ErbB3 inhibitor, based on levels of particular biomarkers and combinations of biomarkers measured in a biological sample obtained from the patient. The methods further comprise optimizing the patient's therapy, selecting the patient for treatment, or treating the patient accordingly. In various aspects the biological samples are sections of a biopsy (e.g., a formalin fixed paraffin embedded biopsy). In other aspects the biomarkers are proteins and/or nucleic acids.

Abstract: Provided are methods for optimizing therapy of, treating a patient having, or selecting (identifying) patients who will benefit from treatment for, a cancer (e.g., a non-hematological cancer; e.g., a gynecological cancer). The methods comprise determining whether the patient will benefit from treatment with an ErbB3 inhibitor (e.g., an anti-ErbB3 antibody), with or without either a taxane or an aromatase inhibitor, or with a taxane or an aromatase inhibitor in the absence of an ErbB3 inhibitor, based on levels of particular biomarkers and combinations of biomarkers measured in a biological sample obtained from the patient. The methods further comprise optimizing the patient's therapy, selecting the patient for treatment, or treating the patient accordingly. In various aspects the biological samples are sections of a biopsy (e.g., a formalin fixed paraffin embedded biopsy). In other aspects the biomarkers are proteins and/or nucleic acids.

Abstract: The present disclosure discloses a multi-interface unified displaying system and method based on virtual reality. The system includes: a plurality of remote desktop proxy servers, respectively built in a corresponding plurality of intelligent electronic devices to obtain current screen images of the intelligent electronic devices; and a virtual reality machine.

Abstract: Provided are methods for optimizing therapy of, treating a patient having, or selecting (identifying) patients who will benefit from treatment for, a cancer (e.g., a non-hematological cancer; e.g., a gynecological cancer). The methods comprise determining whether the patient will benefit from treatment with an ErbB3 inhibitor (e.g., an anti-ErbB3 antibody), with or without either a taxane or an aromatase inhibitor, or with a taxane or an aromatase inhibitor in the absence of an ErbB3 inhibitor, based on levels of particular biomarkers and combinations of biomarkers measured in a biological sample obtained from the patient. The methods further comprise optimizing the patient's therapy, selecting the patient for treatment, or treating the patient accordingly. In various aspects the biological samples are sections of a biopsy (e.g., a formalin fixed paraffin embedded biopsy). In other aspects the biomarkers are proteins and/or nucleic acids.

Abstract: Methods for predicting a therapeutic response in a patient (e.g., a cancer patient) to ErbB3 inhibitors, and methods of treating a cancer patient with targeted therapies.

Abstract: Provided are an image quality adjustment method and system, which are suitable for a video device. The image quality adjustment method comprises: when a video device is started, according to whether the current time falls into a pre-determined time period, executing a corresponding image quality adjustment program; invoking a set value of a corresponding image quality parameter by detecting ambient light; and acquiring a reference value of the corresponding image quality parameter by judging the type of the current video content, and then deciding whether to adjust the image quality parameter by comparing the set value with the reference value, thereby realizing the effect of adaptively adjusting the image quality parameter, thus improving the use convenience of the video device.

Abstract: Provided are methods for optimizing therapy of, treating a patient having, or selecting (identifying) patients who will benefit from treatment for, a cancer (e.g., a non-hematological cancer; e.g., a gynecological cancer). The methods comprise determining whether the patient will benefit from treatment with an ErbB3 inhibitor (e.g., an anti-ErbB3 antibody), with or without either a taxane or an aromatase inhibitor, or with a taxane or an aromatase inhibitor in the absence of an ErbB3 inhibitor, based on levels of particular biomarkers and combinations of biomarkers measured in a biological sample obtained from the patient. The methods further comprise optimizing the patient's therapy, selecting the patient for treatment, or treating the patient accordingly. In various aspects the biological samples are sections of a biopsy (e.g., a formalin fixed paraffin embedded biopsy). In other aspects the biomarkers are proteins and/or nucleic acids.